Appearance of bone marrow lymphocytosis predicts an optimal response to imatinib therapy in patients with chronic myeloid leukemia.
Mustjoki
S
S
Lundán
T
T
Knuutila
S
S
Porkka
K
K
D000328:Adult; D000368:Aged; D001549:Benzamides; D001853:Bone Marrow / Q000473:pathology*; D001854:Bone Marrow Cells / Q000378:metabolism; D002871:Chromosome Banding; D005260:Female; D006801:Humans; D000068877:Imatinib Mesylate; D016130:Immunophenotyping; D007621:Karyotyping; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000473:pathology*; D008214:Lymphocytes / Q000378:metabolism; D008218:Lymphocytosis / Q000188:drug therapy* / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000627:therapeutic use*; D011379:Prognosis; D011743:Pyrimidines / Q000627:therapeutic use*
D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate